Literature DB >> 23225573

Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis.

Dorothea Buck1, Eva Albrecht, Muhammad Aslam, An Goris, Natalie Hauenstein, Angela Jochim, Sabine Cepok, Verena Grummel, Bénédicte Dubois, Achim Berthele, Peter Lichtner, Christian Gieger, Juliane Winkelmann, Bernhard Hemmer.   

Abstract

OBJECTIVE: Intrathecal synthesis of immunoglobulin gamma (IgG) synthesis is frequently observed in patients with multiple sclerosis (MS). Whereas the extent of intrathecal IgG synthesis varies largely between patients, it remains rather constant in the individual patient over time. The aim of this study was to identify common genetic variants associated with the IgG index as a marker of intrathecal IgG synthesis in MS.
METHODS: We performed a genome-wide association study of the IgG index in a discovery series of 229 patients. For confirmation we performed a replication in 2 independent series comprising 256 and 153 patients, respectively. The impact of associated single nucleotide polymorphisms (SNPs) on MS susceptibility was analyzed in an additional 1,854 cases and 5,175 controls.
RESULTS: Significant association between the IgG index and 5 SNPs was detected in the discovery and confirmed in both replication series reaching combined p values of p = 6.5 × 10(-11) to p = 7.5 × 10(-16) . All identified SNPs are clustered around the immunoglobulin heavy chain (IGHC) locus on chromosome 14q32.33 and are in linkage disequilibrium (r(2) range, 0.71-0.95). The best associated SNP is located in an intronic region of the immunoglobulin gamma3 heavy chain gene. Additional sequencing identified the GM21* haplotype to be associated with a high IgG index. Further evaluation of the IGHC SNPs revealed no association with susceptibility to MS in our data set.
INTERPRETATION: The extent of intrathecal IgG in MS is influenced by the IGHC locus. No association with susceptibility to MS was found. Therefore GM haplotypes might affect intrathecal IgG synthesis independently of the underlying disease.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23225573      PMCID: PMC3661208          DOI: 10.1002/ana.23749

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  43 in total

Review 1.  Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors.

Authors:  Alberto Ascherio; Kassandra L Munger
Journal:  Ann Neurol       Date:  2007-06       Impact factor: 10.422

2.  A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

Authors:  B G Weinshenker; P C O'Brien; T M Petterson; J H Noseworthy; C F Lucchinetti; D W Dodick; A A Pineda; L N Stevens; M Rodriguez
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

3.  Immunoglobulin G heavy chain (Gm) allotypes in multiple sclerosis.

Authors:  J P Pandey; J M Goust; J P Salier; H H Fudenberg
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

4.  B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions.

Authors:  S E Baranzini; M C Jeong; C Butunoi; R S Murray; C C Bernard; J R Oksenberg
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

5.  Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

Authors:  Laura Piccio; Robert T Naismith; Kathryn Trinkaus; Robyn S Klein; Becky J Parks; Jeri A Lyons; Anne H Cross
Journal:  Arch Neurol       Date:  2010-06

6.  Jalview Version 2--a multiple sequence alignment editor and analysis workbench.

Authors:  Andrew M Waterhouse; James B Procter; David M A Martin; Michèle Clamp; Geoffrey J Barton
Journal:  Bioinformatics       Date:  2009-01-16       Impact factor: 6.937

7.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

8.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

9.  Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier.

Authors:  Felix Schlachetzki; Chunni Zhu; William M Pardridge
Journal:  J Neurochem       Date:  2002-04       Impact factor: 5.372

10.  Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis.

Authors:  M J Walsh; W W Tourtellotte
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307

View more
  13 in total

1.  Multiple sclerosis: Genetic variability affects CNS IgG production in MS.

Authors:  Jose C Álvarez-Cermeño; Luisa M Villar
Journal:  Nat Rev Neurol       Date:  2015-04-14       Impact factor: 42.937

2.  Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.

Authors:  An Goris; Ine Pauwels; Marte W Gustavsen; Brechtje van Son; Kelly Hilven; Steffan D Bos; Elisabeth Gulowsen Celius; Pål Berg-Hansen; Jan Aarseth; Kjell-Morten Myhr; Sandra D'Alfonso; Nadia Barizzone; Maurizio A Leone; Filippo Martinelli Boneschi; Melissa Sorosina; Giuseppe Liberatore; Ingrid Kockum; Tomas Olsson; Jan Hillert; Lars Alfredsson; Sahl Khalid Bedri; Bernhard Hemmer; Dorothea Buck; Achim Berthele; Benjamin Knier; Viola Biberacher; Vincent van Pesch; Christian Sindic; Annette Bang Oturai; Helle Bach Søndergaard; Finn Sellebjerg; Poul Erik H Jensen; Manuel Comabella; Xavier Montalban; Jennifer Pérez-Boza; Sunny Malhotra; Jeannette Lechner-Scott; Simon Broadley; Mark Slee; Bruce Taylor; Allan G Kermode; Pierre-Antoine Gourraud; Stephen J Sawcer; Bettina Kullle Andreassen; Bénédicte Dubois; Hanne F Harbo
Journal:  Brain       Date:  2015-01-22       Impact factor: 13.501

3.  Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?

Authors:  Jessica Frau; Luisa Maria Villar; Claudia Sardu; Maria Antonietta Secci; Lucia Schirru; Diana Ferraro; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Roberta Bedin; Patrizia Sola; Maria Giovanna Marrosu; Eleonora Cocco
Journal:  J Neurol       Date:  2017-12-22       Impact factor: 4.849

4.  Fast Principal-Component Analysis Reveals Convergent Evolution of ADH1B in Europe and East Asia.

Authors:  Kevin J Galinsky; Gaurav Bhatia; Po-Ru Loh; Stoyan Georgiev; Sayan Mukherjee; Nick J Patterson; Alkes L Price
Journal:  Am J Hum Genet       Date:  2016-02-25       Impact factor: 11.025

Review 5.  Genetics of Multiple Sclerosis: An Overview and New Directions.

Authors:  Nikolaos A Patsopoulos
Journal:  Cold Spring Harb Perspect Med       Date:  2018-07-02       Impact factor: 6.915

Review 6.  Genetics and functional genomics of multiple sclerosis.

Authors:  Woori Kim; Nikolaos A Patsopoulos
Journal:  Semin Immunopathol       Date:  2022-01-12       Impact factor: 9.623

7.  Meta-analysis of global and high throughput public gene array data for robust vascular gene expression discovery in chronic rhinosinusitis: Implications in controlled release.

Authors:  Nitish Khurana; Abigail Pulsipher; Hamidreza Ghandehari; Jeremiah A Alt
Journal:  J Control Release       Date:  2020-11-02       Impact factor: 9.776

8.  Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles.

Authors:  Inger-Lise Mero; Marte W Gustavsen; Hanne S Sæther; Siri T Flåm; Pål Berg-Hansen; Helle B Søndergaard; Poul Erik H Jensen; Tone Berge; Anja Bjølgerud; Aslaug Muggerud; Jan H Aarseth; Kjell-Morten Myhr; Elisabeth G Celius; Finn Sellebjerg; Jan Hillert; Lars Alfredsson; Tomas Olsson; Annette Bang Oturai; Ingrid Kockum; Benedicte A Lie; Bettina Kulle Andreassen; Hanne F Harbo
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

9.  The forgotten tale of immunoglobulin allotypes in cancer risk and treatment.

Authors:  Janardan P Pandey; Zihai Li
Journal:  Exp Hematol Oncol       Date:  2013-02-20

10.  Epitope-specific antibody response is controlled by immunoglobulin V(H) polymorphisms.

Authors:  Bruno Raposo; Doreen Dobritzsch; Changrong Ge; Diana Ekman; Bingze Xu; Ingrid Lindh; Michael Förster; Hüseyin Uysal; Kutty Selva Nandakumar; Gunter Schneider; Rikard Holmdahl
Journal:  J Exp Med       Date:  2014-02-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.